Scholars Central

Case reportPublished 2015

Langerhans Cell Sarcoma: Treatment with Dose-adjusted EPOCH

Authors: Abhisek Swaika, Neha Sood, David M Menke, Asit K Jha, Sikander Ailawadhi

Chemotherapy: Open Access

Volume 4 · Issue 3 · Pages 1–4

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Langerhans cell sarcoma (LCS) is a rare malignancy with no specific defined treatment strategy.Chemotherapy is the preferred option in cases with systemic involvement, though no consensus exists on thepreferred regimen. Case: A sixty-six year old male presented with advanced-stage LCS involving the bone marrow (BM) and spleen. Immunohistochemical analysis of the BM-sample confirmed the diagnosis of LCS. The patient was treated withchemotherapy utilizing dose-adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide and Doxorubicin (DAEPOCH). The patient achieved complete remission and was able to tolerate the entire course (6 cycles) of chemotherapy with continued response at 10 months. Conclusion: Due to the rarity of the disease no standard treatment modality exists; most successful treatment options described are anecdotal reports. Due to the paucity of such data and inability to include enough patients on clinical trials, various combination chemotherapy options have been used for best clinical response. The unattractive response rate to CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in previously described case series and the benefit of Etoposide in treating Langerhans cell histiocytosis and primitive sarcoma regimens along with an acceptable adverse effect profile, had us chose DA-EPOCH for our patient. We demonstrate that DAEPOCH is a tolerable and an efficacious treatment regimen for LCS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Chemotherapy: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalChemotherapy: Open Access
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Abhisek Swaika”
  • BylineArticles whose byline prints “Neha Sood”
  • BylineArticles whose byline prints “David M Menke”
  • BylineArticles whose byline prints “Asit K Jha”
  • BylineArticles whose byline prints “Sikander Ailawadhi”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels